Drug Science partnership to improve patient access to medical cannabis in the UKmarzo 26, 2020
Drug Science Medical Cannabis Working Group has formed a partnership with a leading British producer of medical cannabis to help improve patients access to the medicine in the UK.
The MCWG is a consortium of Drug Science experts, industry partners, patient representatives and policy makers that will develop approaches to improving access of medical cannabis in the UK.
It was launched in 2019 by Drug Science, the UK’s leading independent scientific body on drugs, which is leading the UK’s groundbreaking Project Twenty21, Europe’s first and biggest national medical cannabis registry that is exploring the efficacy of medical cannabis for a number of different chronic and untreatable health conditions.
Improving patient access to medical cannabis
The agreement follows Avida Global’s recent strengthening of its management team.
Ben Iversen joined as its new Chief Finance Officer (CFO) and world-renowned medicinal cannabis expert, Dr Maymon-Pomeranchik, joined its advisory board. Chaired by Lord Mancroft, who has been described as the ‘most knowledgeable parliamentarian on the subject of drugs’, Avida Global aims to be the world’s leading B2B producer of high-grade cannabis oils and isolates.
David Badcock, Drug Science CEO, said, “We are delighted that Avida Global have joined the Drug Science Medical Cannabis Working Group. Our shared vision, which will accelerate access of medical cannabis to patients who need it the most, will be greatly enhanced by the support provided the Avida Global team.”
Avida Global is based in London, England, and was incorporated in 2018. It has 40 hectares licensed for growth on a dedicated farm in north-east Colombia, considered to be one of the best global locations for cultivation of its top-quality plants and availability of highly skilled experts.
Drug Science Founder and Chair of the Scientific Committee, Professor David Nutt, said: “Having Avida Global as part of the team gives us an opportunity to collaborate with much of the exciting clinical research work, they are undertaking in the UK, Israel and Colombia.”
“Avida Global is delighted to partner with the Drug Science Medicinal Cannabis Working Group,” commented David Kirby, CEO Avida Global. “Improving education, access and the quality of medicinal cannabis in the UK is critical to helping improve the lives of millions of people.”